Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2024-08-25 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
半年报董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board meeting resolution announcement from Beijing Shuanglu Pharmaceutical Co., Ltd. It details the convening and voting results of the 9th Board of Directors' third meeting held on August 23, 2024. The key agenda was the approval of the 2024 semi-annual report and its summary. However, the document itself does not contain the semi-annual report or substantive financial data; it only announces the board's approval and references where the report can be found. The document length is short (746 characters), and it serves as an official announcement of a board meeting decision rather than the report itself. Therefore, it fits best under Board/Management Information (MANG) as it relates to board meeting resolutions and decisions.
2024-08-25 Chinese
半年报监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Beijing Shuanglu Pharmaceutical Co., Ltd. regarding the approval of the 2024 semi-annual report and its summary. It states that the Supervisory Board has reviewed and approved the procedures and content of the semi-annual report, confirming its accuracy and compliance. However, the actual semi-annual report is not included in this document; instead, it references where the report and summary can be found (on the CNINFO website and in a newspaper). The document is short (779 characters) and serves as an official announcement of the Supervisory Board's resolution rather than the report itself. According to the rules, such an announcement is best classified as a Regulatory Filing (RNS) because it does not contain the full financial report or substantive financial data but is an official regulatory announcement related to the report.
2024-08-25 Chinese
北京双鹭药业股份有限公司2024年半年度业绩预告
Earnings Release Classification · 95% confidence The document is a 2024 semi-annual performance forecast (业绩预告) for the period January 1, 2024 to June 30, 2024. It provides estimated financial results, including net profit and earnings per share, with explanations for the changes compared to the prior year. It explicitly states that the forecast is preliminary and unaudited, with detailed financial data to be disclosed in the 2024 semi-annual report. The document length is short (1232 characters) and it is a forward-looking earnings forecast rather than a full interim report containing actual financial statements. Therefore, it fits the definition of an Earnings Release (ER) as it announces key highlights of quarterly/periodical financial results rather than a comprehensive interim report (IR). H1 2024
2024-07-10 Chinese
北京双鹭药业股份有限公司关于获得硫酸氨基葡萄糖胶囊药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a drug registration certificate from the National Medical Products Administration. It details the drug's basic information, approval status, market context, and potential impact on the company. The document is short (1346 characters) and serves as a regulatory announcement about a product approval rather than a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about product approval and company disclosure obligations.
2024-07-05 Chinese
北京双鹭药业股份有限公司关于获得依帕司他片药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Beijing SL Pharmaceutical Co., Ltd. regarding the receipt of a drug registration certificate for a pharmaceutical product (依帕司他片). It details the drug's registration approval by the National Medical Products Administration, basic drug information, and potential impact on the company. The document is short (836 characters) and serves as a formal public announcement of regulatory approval rather than a financial report or detailed corporate filing. It does not contain financial data, management changes, voting results, or other report types defined in the filing categories. Therefore, it best fits the category of a Regulatory Filing (RNS), which is a fallback for miscellaneous regulatory announcements that do not fit other categories.
2024-06-28 Chinese
北京双鹭药业股份有限公司2023年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is titled as an announcement regarding the implementation of the 2023 annual equity distribution (dividend) plan approved at the 2023 Annual General Meeting. It details the dividend amount per share, the record date, the ex-dividend date, and the method of dividend payment. It also references the shareholder meeting resolutions approving the dividend plan. The document length is short (2005 characters) and it primarily announces the dividend distribution details rather than providing a full annual report or financial statements. This fits the definition of a Notice of Dividend Amount (DIV) filing, which announces dividend amounts, payment dates, and details for shareholders.
2024-06-27 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.